CVS Health Restores Coverage for Eli Lilly’s Zepbound and Adds Obesity Pill
CVS Health announced it will restore coverage for Eli Lilly's weight loss injection, Zepbound, starting October 1, and add its new obesity pill Foundayo on June 1. This decision supports Eli Lilly in competing with Novo Nordisk by offering equal drug plan access to both companies' GLP-1 medications.
Topics: CVS Health Eli Lilly obesity drugs Wegovy Zepbound